Accustem Sciences Inc.
ACUT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ACUT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ACUT
Accustem Sciences Inc. is a pre-revenue biotech company with a history of operating losses, an accumulated deficit of $10.5M as of June 2026, and a going concern warning from management.
Key risk: Going concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.6M
Cash Runway
—
Lead Asset
MSC (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Accustem Sciences Inc..
Similar companies
Accustem Sciences Inc. is a pre-revenue biotech company with a history of operating losses, an accumulated deficit of $10.5M as of June 2026, and a going concern warning from management.
- Total revenue of $0.1M and net loss of -$0.3M for the period ending 2026-06-30 [sec].
- Shareholders' equity of -$3.4M and total debt of $0.1M as of 2026-06-30 [sec].
- Accumulated deficit of $10,521,599 as of June 30, 2026 [sec_mda].
- Management believes existing cash will only fund operations until August 2026 [sec_mda].
- The company relies on related-party advances and notes payable for financing [sec_mda].
What works
- The company has no material capital expenditure commitments, which may limit cash burn [sec_mda].
- Net cash provided by financing activities has been supported by advances from a related party [sec_mda].
- The company is actively pursuing research funding and product development, indicating ongoing operational efforts [sec_mda].
What to weigh
- The company has a history of operating losses and expects them to continue for the foreseeable future [sec_mda].
- Management states that existing cash and current assets are insufficient to support operations for 12 months from the latest filing date [sec_mda].
- Accumulated deficit has grown steadily, reaching $10.5M as of June 2026 [sec_mda].
- The company will require significant additional cash resources to continue planned research and development activities [sec_mda].
From the filings
Quoted directly from source documents.
Going concern warning: insufficient cash for 12 months
“Management believes that the Company does not have sufficient cash and current assets to support its operations through at least 12 months from the issuance date of these condensed consolidated financial statements”
SEC MD&A · August 14, 2026
Accumulated deficit as of June 30, 2026
“we have $10,521,599 of accumulated deficit as at June 30, 2026”
SEC MD&A · August 14, 2026
Cash runway until August 2026
“we believe our existing cash and cash equivalents will be sufficient to fund our operations and capital expenditure requirements until August 2026”
SEC MD&A · August 14, 2026
Reliance on related-party advances
“net cash provided by financing activities was primarily due to advances from a related party, partially offset by payments on a note payable”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — Management states cash is insufficient for 12 months of operations [sec_mda]
- Accumulated deficit — Deficit of $10.5M as of June 2026, with continued losses expected [sec_mda]
- Dependence on related-party financing — Operating cash flow relies on advances from a related party [sec_mda]
- Negative shareholders' equity — Equity of -$3.4M as of 2026-06-30 [sec]
What to watch
- Ability to secure additional financing or partnerships to extend cash runway beyond August 2026 [sec_mda]
- Progress in research funding and product development milestones [sec_mda]
- Changes in accumulated deficit and operating loss trends in future filings [sec_mda]
- Any new related-party advances or changes in financing structure [sec_mda]
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Accustem Sciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Accustem Sciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
OCF -$249K · Net income -$253K
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for Accustem Sciences Inc.?
Accustem Sciences Inc. is a pre-revenue biotech company with a history of operating losses, an accumulated deficit of $10.5M as of June 2026, and a going concern warning from management.
What is Accustem Sciences Inc.'s lead drug candidate?
Accustem Sciences Inc.'s most advanced tracked candidate is MSC (Phase 2) for Ischemic Stroke.
Who is the CEO of Accustem Sciences Inc.?
Ms. Wendy E. Blosser is the chief executive officer of Accustem Sciences Inc. (ACUT).
Where is Accustem Sciences Inc. headquartered?
Accustem Sciences Inc. (ACUT) is headquartered in New York, NY, United States.
What therapeutic areas does Accustem Sciences Inc. focus on?
Accustem Sciences Inc. develops therapies across Oncology, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.